Virothera

Virothera is a South Korean biotechnology company specializing in the development of next-generation oncolytic virus therapies for hard-to-treat cancers. The company's proprietary Viro-T platform utilizes engineered Herpes Simplex Virus type 1 (HSV-1) to selectively target and destroy tumor cells while stimulating a systemic anti-tumor immune response. Its lead candidate, VT-101, is being developed for the treatment of glioblastoma multiforme (GBM) and is designed to overcome the limitations of existing viral therapies through enhanced targeting and the incorporation of therapeutic transgenes. Virothera aims to provide innovative solutions for solid tumors that are resistant to conventional treatments by leveraging its expertise in viral vector engineering.